Vol. 39 No. 6 (2022): DICIEMBRE
Clinical Expreience

Community acquired meningitis in Santiago, Chile, 2011-2017

Francisca Pinochet Valenzuela
Pontificia Universidad Católica de Chile, Santiago
Bio
Javier Uribe Monasterio
Pontificia Universidad Católica de Chile. Santiago
Bio
Tomás Reyes Barros
Pontificia Universidad Católica de Chile. Santiago
Bio
Sylvia Echavarri Esperinas
P. Universidad Católica de Chile - Complejo Asistencial Sótero del Río.
Bio
Inés Cerón Araya
Pontificia Universidad Católica de Chile. Santiago
Bio
Oscar Felipe Corsi Sotelo
Pontificia Universidad Católica de Chile, Santiago
Bio

Published 2023-01-26

How to Cite

1.
Pinochet Valenzuela F, Uribe Monasterio J, Reyes Barros T, Echavarri Esperinas S, Cerón Araya I, Corsi Sotelo OF. Community acquired meningitis in Santiago, Chile, 2011-2017. Rev. Chilena. Infectol. [Internet]. 2023 Jan. 26 [cited 2026 Jun. 28];39(6). Available from: https://revinf.cl/index.php/revinf/article/view/1679

Abstract

Background: In Chile, there is scarce information on the frequency of the causative microorganisms of community-acquired meningitis (CAM), which is relevant for the choice of empiric treatment.

Aim: To describe the microbiology of CAM in patients over 15 years treated at a public hospital in Santiago (Chile). Methods: Retrospective review of positive cerebrospinal fluid cultures during 2011-2017. Clinical information of the included patients was collected. Cultures considered as contamination and cases of post-surgical meningitis were excluded.

Results: We identified 20 episodes of bacterial meningitis (BM) and six episodes of cryptococcal meningitis (CM) in 2720 cultures. The microorganisms identified in BM cases were Streptococcus pneumoniae (50%), Listeria monocytogenes (25%) and five other agents (25%). All patients with L. monocytogenes infection had at least one well-known risk factor for this infection. Four of the five cases of CM had HIV infection.

Conclusion: Streptococcus pneumoniae was the most frequent causative microorganism of CAM in this series, followed by L. monocytogenes. Current recommendations for empiric CAM regimens adequately consider coverage for S. pneumoniae in all patients and for L. monocytogenes only in those with risk factors. Furthermore, it is relevant to consider CM in cases involving immunocompromised patients.